20 January, 2020
On 15 January 2020, the United States and China signed the long-awaited phase-one trade deal1. The agreement, which addresses issues ranging from Chinese imports of US goods to currency, came as no surprise to the market, as both sides had been publicly discussing the pact since the middle of December. In this market note, Sue Trinh, Senior Macro Strategist, Manulife Investment Management, assesses the significant aspects of the deal and notes that the real test will be in implementing the details of the agreement and setting the agenda for the next phase of talks.
The signing of the phase-one US-China trade deal came as no surprise to investors. Although the agreement contains important steps on market access, intellectual property rights, and currency, many of these had already been announced or implemented before 15 January. Overall, we believe that China will continue to deliver on any commitments that overlap with its self-interest, which ultimately raises the stakes when trying to enforce the deal in areas where it doesn’t comply. As always, the devil is in the detail.
Looking at the substance of the agreement, China has agreed to increase purchases and imports of US goods and services by at least US$200 billion in 2020 and 2021. These include agricultural, manufacturing, and energy products2. Overall, we believe that the agreement on purchase levels seems unrealistic, but China could meet it if the government diverts its current import demand away from other trade partners to the US. Such a move would mean that China’s total imports remain unchanged and global growth would receive no boost. We also note that a larger share of the proposed purchases is slated for 2021 than 2020. This schedule gives China the flexibility to deal with a potentially different administration in the US after the upcoming November elections. China also has several mitigating clauses for purchases, such as slower domestic growth. Furthermore, the US must make goods available for export, which could become an issue with existing export restrictions.
Regarding currency, the agreement contains almost nothing new. China has agreed to provide data that it already discloses through foreign-currency reserves or balance-of-payment data. The other provisions are mostly a reiteration of existing Chinese commitments to the International Monetary Fund and G-20.
Finally, the agreement may be most notable for the issues that it doesn’t address. The core of the US-China economic dispute revolves around several themes, such as tariffs, technology transfer, and Chinese government subsidies, none of which are mentioned in the text. President Trump has stated that a potential phase-two deal and tariff rollback can wait until after the presidential elections in November3. However, as the phase-one deal gives the US the unilateral right to punish China if it fails to deliver on its pledges, tensions could escalate at any time.
From a market perspective, the Chinese renminbi has been a principal beneficiary of the optimism leading up to the deal. Since the contours of the agreement were announced in mid-December last year, the renminbi (both onshore and offshore) has been one of the best-performing emerging-market currencies.
Having said that, we believe that weaker Chinese growth and increased non-trade barriers should lead to another bout of renminbi depreciation. A breakdown in phase-two talks would likely accelerate that trend.
1 Office of the United States Trade Representative: Economic and Trade Agreement between the United States of America and the People’s Republic of China, Phase One, 15 January 2020.
2 The benchmark for purchase amounts will be 2017. In 2017, China bought US$130 billion in goods and US$56 billion in services, 15 January 2020, Wall Street Journal.
3 Reuters: "Trump says he may wait to finish Phase 2 China trade deal until after November," 10 January 2020.
The case for China bonds: A potential hedge against rising inflation
We explain why they think China government bonds and the Chinese renminbi have the potential to act as hedges against US inflation.
ESG investing in Asia - the continuing evolution
As ESG investing in Asia surges, we discuss the key developments in the region’s sustainable fixed-income market and how to identify meaningful investment opportunities for a sustainable future.
Banks are back: a look at three stages of U.S. bank recovery
We explore how U.S. banks prepared to weather the economic tail risk of a pandemic and discuss why we maintain a favorable view of the segment amid prospective signs of continued strength for banks.
The information provided on this website is for informational purposes only and is intended solely for use by Singapore residents and is not intended for distribution to, or use by, any person or entity in the United States, or any jurisdiction or country where such distribution or use would be contrary to law or regulation, or which would subject Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration No. 200709952G) and/or its affiliates (collectively hereafter "Manulife") or any of Manulife's products or services to any registration requirement within such jurisdiction or country. Nothing on this website shall be construed as financial advice or an offer, invitation, solicitation or recommendation by or on behalf of Manulife to any person to buy or sell any Fund and is no indication of trading intent in any Fund managed by Manulife. None of the information or analyses presented are intended to form the basis for any investment decision, and no specific recommendations are intended.
Investments in any Fund are not deposits in, guaranteed or insured by Manulife and involve risks. The value of units in any Fund and any income accruing to it may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. The Fund may use or invest in financial derivative instruments. Investors should read the prospectus and seek advice from a financial adviser, before deciding whether to subscribe for or purchase units in any Fund. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund(s) is/are suitable for him. Copies of the prospectus and the product highlights sheets can be obtained from Manulife or its distributors, for further details (including the risk factors) and charges.
The Manager shall have the absolute discretion to determine whether a distribution is to be made in respect of any Fund as well as the rate and frequency of distributions to be made. The intention of the Manager to make the distribution and the distribution yield for the Fund is not guaranteed, and the Manager may review the distribution policy depending on prevailing market conditions. Distributions may be made out of income, net capital gains and/or capital. Past distribution yields and payments are not necessarily indicative of future distribution yields and payments. Any payment of distributions by the Fund may result in an immediate decrease in the net asset value per unit.
All advertisements or publications provided on this website have not been reviewed by the Monetary Authority of Singapore.
Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration No. 200709952G)